Synthetic Biologics changes clinical and regulatory team
Joseph Sliman will assume the new role after previously serving as the senior medical director and head of patient safety and pharmacovigilance at Vanda Pharmaceuticals, Inc. At Synthetic Biologics, Sliman will be responsible for the design and implementation of all aspects of clinical development, including clinical trials, and will lead Biologics' regulatory initiatives.
"We are pleased to welcome Joe to Synthetic Biologics and expect that his extensive clinical development, regulatory and biotechnology experience - especially in navigating clinical pathways with regulatory agencies - will be vital in moving our infectious disease programs forward," Jeffrey Riley, the CEO of Synthetic Biologics, said.
While working at Vanda, Sliman directed efforts for a new drug application for HETLIOZ, a treatment for non-24-hour disorder in the totally blind. Sliman previously worked as the medical director in vaccines and infectious diseases at MedImmune, Inc., and as an associate medical director at Dynport Vaccine Company.
Sliman will take over for Carol Reed who will continue to contribute to Synthetic Biologics as a clinical and regulatory advisor.
"We are also pleased that Dr. Carol Reed will continue to be part of the Synthetic Biologics' team as a key advisor on clinical development projects," Riley said. "Carol has been integral in moving forward clinical development strategies for our new infectious disease programs and planning the next steps for our Phase II product candidate, Trimesta, for the treatment of multiple sclerosis."
Synthetic Biologics develops product candidates for serious infectious and other diseases.